New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for ...
For the quarter ended September 30, 2025, the Company reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, compared to a net loss applicable to common ...
Andy Wright remembers the morning he woke up from anesthesia after his liver transplant.His wife, Carie Wright, was beside ...
Higher alcohol consumption was linked to greater risk for cirrhosis and liver-related events among patients with metabolic ...
News Medical on MSN
The mechanisms behind thrombocytopenia in patients with portal hypertension and chronic liver disease
Persistent liver injury halts the regenerative capacity of hepatocytes and activates mechanisms that result in the ...
Prime Medicine, Inc. ( PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST ...
Further decompensation in cirrhosis is associated with increased mortality. However, reliable tools to predict further ...
A woman in Delaware has become the first patient to undergo minimally invasive, endovascular surgery with a polymer-based coil. The coil, manufactured by Embolization, Inc., is a vascular embolization ...
An announcement from Galectin Therapeutics ( ($GALT) ) is now available. On November 10, 2025, Galectin Therapeutics announced the presentation of ...
Galectin Therapeutics (GALT) presented a poster and will deliver an oral presentation of the NAVIGATE study analysis at the American Association ...
As of Monday, November 10, Galectin Therapeutics Inc.’s GALT share price has surged by 14.04%, which has investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback